EP1690098A2 - Biological materials and uses thereof - Google Patents

Biological materials and uses thereof

Info

Publication number
EP1690098A2
EP1690098A2 EP04798502A EP04798502A EP1690098A2 EP 1690098 A2 EP1690098 A2 EP 1690098A2 EP 04798502 A EP04798502 A EP 04798502A EP 04798502 A EP04798502 A EP 04798502A EP 1690098 A2 EP1690098 A2 EP 1690098A2
Authority
EP
European Patent Office
Prior art keywords
fibrosis
tieg
smad
compound
ctgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04798502A
Other languages
German (de)
French (fr)
Inventor
Nadia Abdel Wahab
Roger Maxwell Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Publication of EP1690098A2 publication Critical patent/EP1690098A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Definitions

  • the presently claimed invention relates to methods of identifying and/or making compounds for use in the reduction and/or prevention of fibrosis.
  • fibrosis occurs, or indeed the extent of the fibrosis, is influenced by a variety of factors, including the nature, severity and location of the injury to be healed. Fibrosis is most commonly known as scars on the surface of the skin, where it is relatively un-troublesome, except i scarring over large areas. However, fibrosis can also occur in the tissues of internal organs e.g. liver, lung and kidney. In most cases, it is fibrosis in these areas that is most serious because the specialised activity of that organ is unpaired. In the most extreme cases organ failure or death can occur because of that impahment. An example of the importance of fibrosis in the disease state is demonstrated by the occurrence of fibrosis in the kidney (diabetic nephropathy) in diabetes meUitus, a disease now reaching epidemic proportions world-wide.
  • diabetes mellitas is closely linked to a number of secondary complications, especially microvascular related complications. These complications, including the f ⁇ brotic condition nephropathy, usually develop a number of years after the onset of diabetes.
  • Diabetic nephropathy is characterised by excessive deposition of extracellular matrix proteins in the mesangium and basement membrane of the glo erulus and in the renal tubulointerstitium.
  • DN diabetic nephropathy
  • UPDS Group (1998) Lancet 352 pp. 837-853).
  • the prevalence of nephiOpathy varies according to geographical location, type of diabetes, and the length of time since diagnosis. Notwi standing influencing factors, the prevalence of diabetic nephropathy is predicted to increase in the decades ahead (Bagust A et al. (2002) Diabetes Med 19 (Suppl 4): ppl-5).
  • Diabetic nephropathy is a major cause of end-stage renal disease (11), and new therapeutic approaches are required to lknit its development.
  • the pathology of diabetic nephropathy is similar in types 1 and 2 diabetes. Both types of diabetes are associated with similar ullxastractural changes occurring in lddney glomeruli (Osterby , (1992) Diabetologica 35 pp 803- 812).
  • the glomerular basement membrane increases in thickness, and the extracellular matrix of the mesangium expands. It is expansion of the mesangium that is thought to be the main cause of reduced renal function in diabetic nephropathy (Steffes M et al. (1989) Diabetes 38 ppl077-1081).
  • Fibrotic disease is commonly associated with an imbalance in growth factors and hormones, which in turn influence the production of protein expression.
  • the abnormal protein expression in turn leads to the formation of fibrosis.
  • fibrosis is commonly nifluenced by an increase in transforming growth factor- ⁇ present in the fibrotic tissue.
  • Fibrosis is one of the largest groups of disorders for which there is no effective therapy, in part because the mechanism underlying these disorders is influenced by a variety of factors and exact cellular mechanisms have not been elucidated. Therefore, there is a lack of understanding of which, or the nature of, molecular targets that may provide targets around which anti- f ⁇ brotic therapies may be based.
  • TGF- ⁇ transforming growth factor- ⁇
  • TGF- ⁇ has a number of physiological roles including involvement in immunity and epithelial proliferation (McCartney-Francis N et al. (1998) Int. Rev. Immunol. 16 pp. 553-580). These varying physiological effects mean that TGF- ⁇ is unlikely to be a clinically advantageous target. Blocldng the actions of TGF- ⁇ may have multiple effects on the organism, causing unwanted and potentially serious side- effects.
  • Transforming growth factor- ⁇ causes .fibrosis by the direct induction of collagen and matrix synthesis. Additionally, TGF- ⁇ is also able to induce the expression of other molecules that take part in and/or influence the pathways causing fibrosis.
  • One such protein is connective tissue growth factor (CTGF), which induces proliferation, collagen synthesis and chemotaxis in mesenchymal cells (Moussad E et al. (2000) Molec Genet Metab. 71 pp.276-292).
  • CTGF CCN2
  • CCN2 is a 38 kDa secreted protein with multiple domains, encoded by an immediate-early gene and is a member of the CCN protein family (Bork et al. (1993) Febs Lett.
  • CTGF has been shown to directly bind BMP4 and TGF- ⁇ through its von Willebrand type C domam, leading to inhibition of BMP and enhancement of TGF- ⁇ signalling (Abreu et al. (2002) Nat. Cell. Biol. 4 pp. 599-604).
  • CTGF has also been shown to bind to integrins (Babic et al. (1999) Mol. Cell Biol. 19 p ⁇ .3811-3815) and it is possible that this interaction is important in mediating some of the cellular phenomena that CTGF induces.
  • CTGF is over-expressed hi a variety of fibrotic disorders, mcluding diabetic nephropathy (Wahab N et al. (2001) Biochem J. 359 pp.77-87). i fact, increasing levels of CTGF expression have been shown to correlate with increasing severity and speed of progression of diabetic nephropathy (Ito Y et al. (1998) Kidney Int. 53 pp.853-886).
  • CTGF may be a potentially useful molecular indicator of the fibrotic response.
  • CTGF has not yet been shown to directly induce renal fibrosis in vivo, but, when injected subcutaneously along with TGF- ⁇ , induces sustained dermal fibrosis in rats (Mori T et al. (1999) J. Cell. Physiol. 181 pp 153-159).
  • TGF- ⁇ directly induces CTGF expression, at least in part through elements in the CTGF promoter (Holmes A. et al. (2001) J. Biol. Chem. 276 pp.10594-10601). In fact, the control of CTGF gene expression is thought to lie chiefly at the level of transcription (reviewed in 8).
  • SMADs facilitate gene expression by acting as trans criptional co- modulators to recruit transcription factors to form an active transcriptional complex (Roberts A (1999) Microbes Infect 1 pp.1265-1273 and Wrana J (2000) Sci STKE 23 RE1). The transcription factors recruited vary depending on the gene and cell type of interest.
  • TGF- ⁇ the diversity and specificity of the biological effects of TGF- ⁇ are due, hi part, to the interaction of the general TGF- ⁇ signalling pathway with other pathways, the nature of which depends on the cell type or target gene of interest (Mulder K (2000) Growth Factor Rev 11 pp23-35).
  • TGF- ⁇ exerts its cellular effects via the Smad signalling pathway.
  • the Smad pathway provides the main signal transduction route downstream of TGF- ⁇ receptors (Massague et al (2000) Cell 103 pp. 295-309).
  • the TGF- ⁇ receptors dimerise and autophosphorylate. This in turn phosphorylates Smad 2 and Smad 3 (Itoh et al. (2000) Eur J. Biochem 267 pp.6954-6967).
  • Smad 2 and Smad 3 then form a complex with Smad 4, which translocates into the nucleus where they co-operate with other transcription factors to regulate transcription of the many TGF- ⁇ - responsive genes containing a Smad binding element (SBE) in their promoters.
  • Smad 7 Smad binding element
  • Smad 7 protein interacts with one or more of the E3-ubiquitin ligases, Smurfl and Smurf2, in the nucleus.
  • the Smad 7-Smurf complex translocates to the plasma membrane where Smurf induces ubiquitination and degradation of the TGF- ⁇ receptors (Kavsak et al (2000) Mol Cell 6 pp.1365-1375).
  • the degradation of the TGF- ⁇ receptors prevents further phosphorylation of Smad 2 and Smad 3.
  • Smad 7 provides a negative feedback response to Ihnit the effect of TGF- ⁇ .
  • Smad 7 gene has been reported to be suppressed by the transcription factor, TIEG which binds to a GC box in the proximal promoter region (Johnsen et al. (2002) Oncogene 21 pp. 5783-5790).
  • TIEG 1 and 2 are potent transcriptional repressors related to the Spl family of transcription factors. Their genes encode zinc-finger ruppel-like proteins whose over-expression mimics the effect of TGF- ⁇ hi different cell types (Cook et al. (1998) J. Biol. Chem.).
  • CTGF enhances the TGF- ⁇ signalling pathway by decreasing the availability of Smad 7, dependent on increased TIEG production in response to CTGF.
  • a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis comprising the steps:
  • the method further comprises the step of isolation of a test compound which is capable of causing no change or an increase in Smad-7 expression and/or no change or a decrease in TIEG expression hi a method according to the first aspect of the invention.
  • the isolated compound may then be optionally formulated into a composition further comprising a pharmaceutically acceptable carrier, excipient and/or diluent.
  • the compound affects directly the interaction between CTGF and TIEG.
  • the compound interacts with CTGF and/or TIEG hi order to reduce and/or prevent the effect of CTGF on TIEG and/or Smad- 7 expression.
  • the compound affects indirectly the interaction between CTGF and TIEG.
  • the compound interacts with at least one fiirther compound, which in turn interacts with CTGF or TIEG in order to reduce and/or prevent the effect of CTGF on TIEG and/or Smad-7 expression.
  • a compound for use in the manufacture of a medicament for reduction and/or prevention of fibrosis characterised in that the compound reduces and/or prevents CTGF suppression of Smad 7 expression and or reduces and/or prevents induction of TIEG expression.
  • the compound is identified and/or made by the method of the first aspect of the invention.
  • the compound is at least one selected from polypeptides, antibody molecules and antisense nucleotides.
  • the compound is an antibody molecule.
  • antibody molecule shall be taken to refer to any one of an antibody, an antibody fragment, or antibody derivative. It is intended to embrace wildtype antibodies, synthetic antibodies, recombii ant antibodies or antibody hybrids, such as, but not limited to, a single-chah modified antibody molecule produced by phage-display of immunoglobulin light and/or heavy chain variable and/or constant regions, or other inmiunohiteractive molecule capable of binding to an antigen hi an hnmunoassay format that is known to those skilled in the art.
  • antibody derivative refers to any modified antibody molecule that is capable of bmding to an antigen in an immunoassay format that is known to those skilled in the art, such as a fragment of an antibody (e.g. Fab or Fv fragment), or a modified antibody molecule that is modified by the addition of one or more amino acids or other molecules to facilitate coupling the antibodies to another peptide or polypeptide, to a large carrier protein or to a solid support (e.g. the a ino acids tyrosine, lysine, glutamic acid, aspartic acid, cysteine and derivatives thereof, NH -acetyl groups or COOH-te ⁇ nrnal arnido groups, amongst others).
  • a fragment of an antibody e.g. Fab or Fv fragment
  • modified antibody molecule that is modified by the addition of one or more amino acids or other molecules to facilitate coupling the antibodies to another peptide or polypeptide, to a large carrier protein or to a solid support (e.g.
  • antisense oligonucleotides we mean single-stranded nucleic acids, which can specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or RNA-DNA duplex is formed. These nucleic acids are often termed “antisense” because they are complementary to the sense or coding strand of the gene. Recently, formation of a triple helix has proven possible where the oligonucleotide is bound to a DNA duplex. It was found that oligonucleotides could recognise sequences in the major groove of the DNA double helix. A triple helix was formed thereby. This suggests that it is possible to synthesise sequence-specific molecules which specifically bind double-stranded DNA via recognition of major groove hydrogen binding sites.
  • oligonucleotides By binding to the target nucleic acid, tlie above oligonucleotides can inhibit the function of the target nucleic acid. This could, for example, be a result of blocking the transcription, processing, poly (A) addition, replication, translation, or promoting inhibitory mechanisms of the cells, such as promoting RNA degradations.
  • Antisense oligonucleotides are prepared in the laboratory and then introduced into cells, for example by microinjection or uptake from the cell culture medium into the cells, or they are expressed in cells after rransfection with plasmids or retroviruses or other vectors carrying an antisense gene.
  • a compound of the second aspect of the invention for use in the treahnent and/or prevention and/or diagnosis of a fibrotic disease.
  • the compound is used in the manufacture of a medicament for the treatment and/or prevention and/or diagnosis of a fibrotic disease.
  • the fibrotic disease is one selected from diabetic nephropathy, non-diabetic kidney failure, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderrna, retinal fibrosis, radiation fibrosis, keloid scar formation and cancer-associated fibrosis
  • the disease is diabetic nephropathy.
  • a fourth aspect of the invention there is provided a method of treating and/or preventing fibrotic disease comprising amninistering a therapeutically or prophylactically effective dose, or plurality of doses, of a compound identified and/or made according to the method of the first aspect of the invention.
  • the fib otic disease is one selected from diabetic nephropathy, non-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderma, retinal fibrosis, radiation fibrosis, keloid scar formation and cancer-associated fibrosis.
  • the disease is diabetic nephropathy.
  • HMC Serum-starved human mesangial cells
  • Serum-starved HMC were exposed to rCTGF/V5 fusion protein for different periods of time, after which cell lysates were prepared and the TIEG and ⁇ -actin levels analysed by Western blotting. A representative blot of the three independent experiments (three replicate cultures per condition per experiment) that were performed is shown.
  • Figure 4 TIEG mediates CTGF-dependent down-regulation of Smad 7 expression level.
  • Serum-starved HMC were exposed to tlie conditions indicated in the figure. After 24 h, cell lysates were prepared, and the TIEG, Smad 7, and ⁇ -actin levels analysed by Western blotting. A representative blot of the three independent experiments (three rephcate cultures per condition per experiment) that were performed is shown.
  • HMC Human mesangial cells
  • TGF- ⁇ inducible early gene (TLEG) antibodies were a gift from Dr. Steven Johnson (Mayo Foundation, Minnesota, USA).
  • Recombinant CTGF was expressed in transformed HMC and purified from the medium using Talon metal affinity resin, as reported previously (Wahab et al (2001) Biochem J. 359 pp. 77-87).
  • TGF- ⁇ was purchased from R & D Systems (Abingdon, Oxfordshire, U.K.).
  • Cells were lysed in reducing SDS-PAGE loading buffer and immediately scraped off the plate. Cell lysates were sonicated for 10 sec to shear DNA. Samples were boiled for 5 min and resolved on 4-12% gradient gels by SDS-PAGE. Proteins were transferred onto a polyvinyiidene difluoride membrane filter (Irmnobilin-P, MiUipore, Bedford, U.K.) ushig a BioRad transfer apparatus. Blots were incubated in blocking buffer containing Ix TBS, 0.1% Tween-20 with 5% (w/v) non-fat dry milk, for 1 hour.
  • Ix TBS 0.1% Tween-20 with 5% (w/v) non-fat dry milk
  • Immunodetection was performed by incubating the blots in primary antibody at the appropriate dilution in antibody dilution buffer (lx TBS, 0.1% Tween-20 with 5% BSA), overnight at 4°C. Blots were then washed 3 times with washing buffer (lx TBS, 0.1% Tween-20) and incubated with secondary horseradish peroxidase (HRP)-conjugated antibodies for 1 hour at room temperature. Bound antibodies were visualised ushig the enhanced chemiluiniiiescence reagent Luniinol (Autogen Bioclear UK Ltd, Wiltslrire, UK). Pre- stained molecular weight standards (Amersham International PLC, Amersham, UK) were used to monitor protein migration.
  • EDTA 1 mM EGTA, 0.2 mM TLCK, 1 mM N-ethyhnaleimide, 0.1 mM TPCK, and 2 nM PMSF, Sigma), 1 mM NaF, 1 mM Na 3 V0 4 ].
  • Nonidet P40 was added to a final concentration of 0.6% (v/v) and vigorously vortex-mixed for 10 seconds.
  • the nuclei were pelleted at 4°C by centrifugation for 5 min at 12000 x g.
  • the nuclear pellet was washed once with buffer A and coUected by centrifugation.
  • the pellet was then re-suspended in 500 ⁇ l of buffer B (10 rnM Hepes, pH 7.4, 1.5 mM MgC12, 450 mM NaCl, lx protease inhibitors cocktail, 1 mM NaF, ImM Na3V04, 20% (v/v) glycerol) and vortex-mixed for 15 min at 4°C.
  • the lysate was centrifuged at 12000 x g for 5 min at 4°C and the supernatant containing the nuclear proteins transferred to a fresh vial. Protein concentration was measured by Bradford assay. Extracts were stored at -70°C until further use.
  • TIEG and CTGF antisense oligonucleotide (2 ⁇ M) or a CG-matched randomised sequence oligonucleotide (negative control) was added directly to cultures 30 min prior any other treatments (Wahab et al (2002) J Am Soc Nephrol 13 pp .2437-2445).
  • the SBE4-luc reporter gene construct was transfected into 25 x 10 6 transformed human mesangial cells (THMC), by electroporation, at a concentration of 15 ⁇ g together with 5 ⁇ g of pSV- ⁇ -galactosidase control Vector (Promega, Southampton, UK), using conditions described previously (Wahab et al (2001) Biochem J. 359 pp. 77-87).
  • Equal amounts (0.5 ⁇ l) of the reverse transcription reaction (20 ⁇ l) were subjected to PCR amplification hi a 100 ⁇ l volume containing 10 ⁇ l of 10 x PCR buffer, 16 ⁇ l dNTPs (1.25 mM each), 2 mM MgC12, 0.5 ⁇ M of each specific primer and 1.25 U Amplitaq DNA polymerase (Gibco BRL).
  • Amplification was started with 5 min of denaturation at 94°C, followed by 5 27 PCR cycles for all genes except the housekeeping gene glyceraldehyde- 3-phosphate dehydrogenase (GAPDH) where 24 PCR cycles were used. Each cycle consisted of 60 seconds at 94°C, 60 seconds at 55°C and 60 seconds at 72°C The final extension was for 10 min at 72°C. GAPDH was co-amplified to aUow semi-quantitative comparison of PCR products and to l o confirm equivalent use of total RNAs .
  • GAPDH housekeeping gene glyceraldehyde- 3-phosphate dehydrogenase
  • the amount of reverse transcription reaction used for the amplification (0.5 ⁇ l) was selected as being non-saturating for the PCR product of all genes under investigation after the stated number of amplification cycles.
  • the 15 sequences of primers were designed from the published sequences of the human genes and are hsted in Table 1.
  • CTGF effect of CTGF on the activation of receptor-regulated Smads (Smad 2 and Smad 3) was investigated by incubating serum-starved HMC in the presence or absence of CTGF, TGF- ⁇ , or in the presence of both CTGF and TGF- ⁇ for 2 hours.
  • TGF- ⁇ -enhanced activity was markedly reduced in the presence of either CTGF or TIEG antisense (3-2 fold) but not with the control oligonucleotides.
  • the antisense, but not the control oligonucleotides also markedly reduced the reporter activity when both TGF- ⁇ and CTGF were present together.
  • CTGF-dependent down-regulation of Smad 7 was also studied h relation to the upregulation of the TGF- ⁇ -responsive genes, pl5INK4, PAI-1, and collagen III. Semrn-starved cells were incubated for 48 hours in the presence of different combinations of CTGF, TGF- ⁇ , CTGF+TGF- ⁇ , CTGF+TIEG antisense and control oligonucleotides and either TGF- ⁇ +TGF antisense and control oligonucleotides or TIEG antisense and control oligonucleotides. RNA was extracted and used for semi-quantitative RT-PCR analysis. Figures 6A and B demonstrate that CTGF resulted h a 60% reduction of Smad 7 expression level. However, CTGF has no significant effect on either PAI-1 or collagen III gene transcription. In contrast, pl5 expression level appears to be enhanced (5-fold) under the same conditions.
  • TGF- ⁇ resulted in induction of transcription of all four genes as they contain one or more SBE in their promoters.
  • CTGF together with TGF- ⁇ , resulted in reduction of Smad 7 (55%) and maximal induction of pi 5, PAI-1 and collagen III transcription.
  • TGF- ⁇ activity is limited by the negative feedback loop of the signalling pathway, provided by Smad 7.
  • CTGF blocks this negative feedback loop by inhibition of Smad 7 expression via TIEG, allowing continued activation of the TGF- ⁇ signalling pathway.
  • Example 2 Screening method for identifying compounds inhibitin CTGF induced fibrosis
  • Screening for compounds possessing fibrosis inhibitory properties is conducted by testing the ability of each compound to block, for example, the induction of TIEG hi HMC treated with CTGF.
  • the screening method is conducted using human mesangial cells (HMC) pre-incubated for 30 lninutes with or without the potential inhibitor. These cells are then stimulated with CTGF-V5 fusion protein (40 ng/ml) in the presence or absence of the potential inhibitor for 2 hours. After washing the cell layer with cold PBS, the cells are lysed in RIP A buffer and the lysate assayed for TIEG by ELISA.
  • NUNC microtifre plates are coated overnight at 4°C with either lysate or with standard dilutions of r-TIEG to provide a standard curve.
  • Recombinant TIEG protein is created from full length TIEG cDNA by cloning into the PcDNA 3.1/V5-His Topo vector (InVitrogen). This vector can be transfected hito a mammalian cell line to express TIEG-fusion protein.
  • the TIEG fusion protein is purified from cell lysates using probond nickel- chelating resin.
  • Anti-TIEG antibody is available from Dr. Steven Johnson (Mayo Foundation, Minnesota, USA) or can be raised in rabbits against the TIEG fusion protein using conventional methods.
  • Example 3 Pharmaceutical formulations and administration.
  • the compounds of the invention wUl normally be adrninistered orally or by any parenteral route, in the form of a pharmaceutical formulation comprising the active ingredient, optionally in the form of a non-toxic organic, or inorganic, acid, or base, addition salt, in a pharmaceutically acceptable dosage fo ⁇ n.
  • the compositions may be administered at varying doses.
  • the compounds of the invention can be adnhnistered alone but will generally be administered in admixture with a suitable pharmaceutical excipient diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • the compounds of the invention can be administered orally, buccaUy or sublingually in the form of tablets, capsules, ovules, elixhs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed- or controlled-release applications.
  • the compounds of the invention may also be a ⁇ ninistered via intracave ⁇ iosal injection.
  • Such tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably com, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation bhiders such as polyvinylpyrxolidone, hydroxypropylmethylcellulose (HPMC), hydroxy-propylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as ' magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
  • excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine
  • disintegrants such as starch (preferably com, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex si
  • Solid compositions of a sinrUar type may also be employed as fillers in gelatin capsules.
  • Preferred excipients hi this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols.
  • the compounds of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
  • the compounds of the invention can also be adniinistered parenteraUy, for example, intravenously, intra-arterially, intraperitoneally, intrathecaUy, intraventricularly, intrastemally, infracranially, intra-muscularly or subcutaneously, or they may be administered by infusion techniques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
  • the aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary.
  • the preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled hi the art.
  • Formulations suitable for parenteral amnmisfration hi include aqueous and non- aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the ⁇ itended recipient; and aqueous and non-aqueous sterile suspensions
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, hnmediately prior to use.
  • sterile liquid carrier for example water for injections, hnmediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • the daily dosage level of the compounds of the mvention will usually be from 1 mg/kg to 30 mg/kg.
  • the tablets or capsules of the compound of the invention may contain a dose of active compound for administration singly or two or more at a time, as appropriate.
  • the physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient.
  • the above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
  • the compounds of the invention can also be adnhnistered hitranasally or by hihalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised contahier, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoroniethane, trichlorofluoromethane, dichlorotetrafluoro- ethane, a hydrofluoraalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A3 or 1,1,1,2,3,3,3-heptafluoropiOpane (HFA 227EA3), carbon dioxide or other suitable gas.
  • a suitable propellant e.g. dichlorodifluoroniethane, trichlorofluoromethane, dichlorotetrafluoro- ethane, a hydrofluoraalkane such as 1,1,1,2-tetrafluoro
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g. ushig a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate.
  • Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the mvention and a suitable powder base such as lactose or starch.
  • Aerosol or dry powder formulations are preferably arranged so that each metered dose or "puff delivers an appropriate dose of a compound of t he invention for delivery to the patient. It will be appreciated that the overall dahy dose with an aerosol wiU vary from patient to patient, and may be administered in a single dose or, more usually, in divided doses throughout the day.
  • the compounds of the invention can be administered in the form of a suppository or pessary, or they may be applied topicaUy in the form of a lotion, solution, cream, ointment or dusting powder.
  • the compounds of the invention may also be transdermally adrninistered, for example, by the use of a skin patch. They may also be a ⁇ ninistered by the ocular route, particularly for treating diseases of the eye.
  • the compounds of the invention can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions hi isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.
  • the compounds of the mvention can be formulated as a suitable ointment containing the active compound n o suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyox ⁇ ropylene compound, emulsifying wax and water.
  • a suitable lotion or cream suspended or dissolved hi, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol and water.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usuaUy sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouth-washes comprising the active ingredient in a suitable liquid carrier.
  • oral or topical administration of the compounds of the invention is the preferred route, being the most convenient.
  • the drug may be administered parenteraUy, e.g. sublingually or buccaUy.
  • a compound of the invention is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will detemih e the dosing regimen and route of administration which will be most appropriate for a particular animal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

The invention provides a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps: providing a cell type capable of expressing TIEG and/or Smad-7; providing a test compound; providing an amount of CTGF or a functional equivalent thereof, exposing the cell type to the test compound; subsequently or simultaneously exposing the cell type to the CTGF or functional equivalent thereof; detecting and/or measuring the expression of Smad-7 and TIEG; and comparing the amount of Smad-7 and/or TIEG expressed in the presence of the test compound with the amount of Smad-7 and/or TIEG produced detected and/or measured in the absence of a test compound; determining if a compound reduces and/or prevents fibrosis on the basis that it causes no change or an increase in Smad-7 expression and/or no change or a decrease in TIEG expression. There is also provided compounds for reducing and/or preventing fibrosis and uses of such compounds.

Description

BIOLOGICAL MATERIALS AND USES THEREOF
The presently claimed invention relates to methods of identifying and/or making compounds for use in the reduction and/or prevention of fibrosis.
When biological tissue is injured, both the injury and the associated inflammatory response can cause the death of cells. When cell death occurs, new tissue is synthesised to replace the dead or dying cells. The synthesis of new tissue falls under two categories, the regeneration of specialised cells; and an increase in connective tissue. In some pathological conditions the connective tissue increase dominates the healing process, leading to the formation of fibrotic - tissue. In fibrosis, the new tissue has repaired any structural defect in the tissue, but has impaired its own function by replacing the specialised cells by connective tissue and connective tissue cells.
Whether fibrosis occurs, or indeed the extent of the fibrosis, is influenced by a variety of factors, including the nature, severity and location of the injury to be healed. Fibrosis is most commonly known as scars on the surface of the skin, where it is relatively un-troublesome, except i scarring over large areas. However, fibrosis can also occur in the tissues of internal organs e.g. liver, lung and kidney. In most cases, it is fibrosis in these areas that is most serious because the specialised activity of that organ is unpaired. In the most extreme cases organ failure or death can occur because of that impahment. An example of the importance of fibrosis in the disease state is demonstrated by the occurrence of fibrosis in the kidney (diabetic nephropathy) in diabetes meUitus, a disease now reaching epidemic proportions world-wide.
The incidence of diabetes melhtus has undergone a global increase in recent years. In particular this is due to a dramatic increase in type 2 diabetes (late- onset diabetes) (Silink M (2002), Horm. Res. 57 (Suppl 1) pp. 1-5). Diabetes mellitas is closely linked to a number of secondary complications, especially microvascular related complications. These complications, including the fϊbrotic condition nephropathy, usually develop a number of years after the onset of diabetes.
Diabetic nephropathy is characterised by excessive deposition of extracellular matrix proteins in the mesangium and basement membrane of the glo erulus and in the renal tubulointerstitium.
Genetic background is thought to be important in detenxuning susceptibility to diabetic nephropathy (DN) (Quinn M et al, (1996) Diabetologica 39 pp 940-945), but the cmcial hήtiating factor is believed to be exposure of tissues to chronic hyperglycaemia (UKPDS Group, (1998) Lancet 352 pp. 837-853). The prevalence of nephiOpathy varies according to geographical location, type of diabetes, and the length of time since diagnosis. Notwi standing influencing factors, the prevalence of diabetic nephropathy is predicted to increase in the decades ahead (Bagust A et al. (2002) Diabetes Med 19 (Suppl 4): ppl-5). Diabetic nephropathy is a major cause of end-stage renal disease (11), and new therapeutic approaches are required to lknit its development. The pathology of diabetic nephropathy is similar in types 1 and 2 diabetes. Both types of diabetes are associated with similar ullxastractural changes occurring in lddney glomeruli (Osterby , (1992) Diabetologica 35 pp 803- 812). The glomerular basement membrane increases in thickness, and the extracellular matrix of the mesangium expands. It is expansion of the mesangium that is thought to be the main cause of reduced renal function in diabetic nephropathy (Steffes M et al. (1989) Diabetes 38 ppl077-1081). As the mesangial matrix expands, it impinges on glomerular capillaries, reducing the surface available for filtration and narrowing or occluding the lumen. Tubulointerstitial fibrosis also occurs in diabetic nephropathy, in addition to glomerulosclerosis. The progressive loss of renal function correlates with the occurrence of advancing interstitial fibrosis in other renal disorders (Risdon R et al. (1968) Lancet 2 7564 pp363-366).
Fibrotic disease is commonly associated with an imbalance in growth factors and hormones, which in turn influence the production of protein expression. The abnormal protein expression in turn leads to the formation of fibrosis. For example, fibrosis is commonly nifluenced by an increase in transforming growth factor-β present in the fibrotic tissue.
Fibrosis is one of the largest groups of disorders for which there is no effective therapy, in part because the mechanism underlying these disorders is influenced by a variety of factors and exact cellular mechanisms have not been elucidated. Therefore, there is a lack of understanding of which, or the nature of, molecular targets that may provide targets around which anti- fϊbrotic therapies may be based.
In the case of diabetic nephropathy, studies have shown that glucose can induce matrix synthesis, at least i part, by the actions of transforming growth factor-β (TGF-β) (Ziyadeh F et al. (2000) Proc Nat! Acad Sci USA 97 pp. 8015-8020).
However, TGF- β has a number of physiological roles including involvement in immunity and epithelial proliferation (McCartney-Francis N et al. (1998) Int. Rev. Immunol. 16 pp. 553-580). These varying physiological effects mean that TGF-β is unlikely to be a clinically advantageous target. Blocldng the actions of TGF-β may have multiple effects on the organism, causing unwanted and potentially serious side- effects.
Transforming growth factor-β causes .fibrosis by the direct induction of collagen and matrix synthesis. Additionally, TGF-β is also able to induce the expression of other molecules that take part in and/or influence the pathways causing fibrosis. One such protein is connective tissue growth factor (CTGF), which induces proliferation, collagen synthesis and chemotaxis in mesenchymal cells (Moussad E et al. (2000) Molec Genet Metab. 71 pp.276-292). CTGF (CCN2) is a 38 kDa secreted protein with multiple domains, encoded by an immediate-early gene and is a member of the CCN protein family (Bork et al. (1993) Febs Lett. 327 pp 125-130; Perbal et al. (2001) Mol. Patho . 54 pp 57-79). However, the molecular mechanism(s) by which it functions have not been fully elucidated. The presence of multiple domains in CTGF suggests that it interacts with a plurality of other factors. CTGF has been shown to directly bind BMP4 and TGF-β through its von Willebrand type C domam, leading to inhibition of BMP and enhancement of TGF-β signalling (Abreu et al. (2002) Nat. Cell. Biol. 4 pp. 599-604). CTGF has also been shown to bind to integrins (Babic et al. (1999) Mol. Cell Biol. 19 pρ.3811-3815) and it is possible that this interaction is important in mediating some of the cellular phenomena that CTGF induces.
CTGF is over-expressed hi a variety of fibrotic disorders, mcluding diabetic nephropathy (Wahab N et al. (2001) Biochem J. 359 pp.77-87). i fact, increasing levels of CTGF expression have been shown to correlate with increasing severity and speed of progression of diabetic nephropathy (Ito Y et al. (1998) Kidney Int. 53 pp.853-886).
Hence, CTGF may be a potentially useful molecular indicator of the fibrotic response. CTGF has not yet been shown to directly induce renal fibrosis in vivo, but, when injected subcutaneously along with TGF-β, induces sustained dermal fibrosis in rats (Mori T et al. (1999) J. Cell. Physiol. 181 pp 153-159).
In noπnal fϊbroblast cells, TGF-β directly induces CTGF expression, at least in part through elements in the CTGF promoter (Holmes A. et al. (2001) J. Biol. Chem. 276 pp.10594-10601). In fact, the control of CTGF gene expression is thought to lie chiefly at the level of transcription (reviewed in 8).
In general, little is known about the regulation of TGF-β signalling i the kidney or TGF-β-induced CTGF gene expression. However, studies employmg other cell types identified a central, general role of SMADs in the TGF- β-induced expression of target genes. Current thinking is that SMADs facilitate gene expression by acting as trans criptional co- modulators to recruit transcription factors to form an active transcriptional complex (Roberts A (1999) Microbes Infect 1 pp.1265-1273 and Wrana J (2000) Sci STKE 23 RE1). The transcription factors recruited vary depending on the gene and cell type of interest. In other words, the diversity and specificity of the biological effects of TGF-β are due, hi part, to the interaction of the general TGF- β signalling pathway with other pathways, the nature of which depends on the cell type or target gene of interest (Mulder K (2000) Growth Factor Rev 11 pp23-35).
TGF-β exerts its cellular effects via the Smad signalling pathway. The Smad pathway provides the main signal transduction route downstream of TGF- β receptors (Massague et al (2000) Cell 103 pp. 295-309). On binding TGF-β, the TGF- β receptors dimerise and autophosphorylate. This in turn phosphorylates Smad 2 and Smad 3 (Itoh et al. (2000) Eur J. Biochem 267 pp.6954-6967). Smad 2 and Smad 3 then form a complex with Smad 4, which translocates into the nucleus where they co-operate with other transcription factors to regulate transcription of the many TGF-β- responsive genes containing a Smad binding element (SBE) in their promoters. One such induced gene is Smad 7.
Smad 7 protein interacts with one or more of the E3-ubiquitin ligases, Smurfl and Smurf2, in the nucleus. The Smad 7-Smurf complex translocates to the plasma membrane where Smurf induces ubiquitination and degradation of the TGF-β receptors (Kavsak et al (2000) Mol Cell 6 pp.1365-1375). The degradation of the TGF-β receptors prevents further phosphorylation of Smad 2 and Smad 3. Hence, Smad 7 provides a negative feedback response to Ihnit the effect of TGF- β. The expression of the Smad 7 gene has been reported to be suppressed by the transcription factor, TIEG which binds to a GC box in the proximal promoter region (Johnsen et al. (2002) Oncogene 21 pp. 5783-5790).
TIEG 1 and 2 are potent transcriptional repressors related to the Spl family of transcription factors. Their genes encode zinc-finger ruppel-like proteins whose over-expression mimics the effect of TGF-β hi different cell types (Cook et al. (1998) J. Biol. Chem.).
In the process of developing this invention, the inventors have demonstrated that CTGF enhances the TGF-β signalling pathway by decreasing the availability of Smad 7, dependent on increased TIEG production in response to CTGF.
Therefore, in a first aspect of the invention there is provided a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps:
(a) providing a cell type capable of expressing TIEG and/or Smad-7
(b) providing a test compound
(c) providing an amount of CTGF or a functional equivalent thereof (d) exposing the cell type to the test compound
(e) subsequently or simultaneously exposing the cell type to the CTGF or a functional equivalent thereof (f) detecting and/or measuring the expression of Smad-7 and/or TIEG
(g) comparing the amount of Smad-7 and/or TIEG expressed in the presence of a test compound with the amount of Smad-7 and/or TIEG produced detected and/or measured in the absence of a test compound
(h) determining if a compound reduces and/or prevents fibrosis on the basis that it causes no change or an increase in Smad-7 expression and/or no change or a decrease in TIEG expression.
By "functionally equivalent" we mean a compound that has substantiaUy the same effect as CTGF on one or more of the following activities, the induction of TIEG expression and/or suppression of Smad-7 expression. This can be demonstrated readily using the methods of detecting TIEG and Smad-7 expression provided by example 1.
Optionally, the method further comprises the step of isolation of a test compound which is capable of causing no change or an increase in Smad-7 expression and/or no change or a decrease in TIEG expression hi a method according to the first aspect of the invention. The isolated compound may then be optionally formulated into a composition further comprising a pharmaceutically acceptable carrier, excipient and/or diluent.
Preferably, the compound affects directly the interaction between CTGF and TIEG. In other words, the compound interacts with CTGF and/or TIEG hi order to reduce and/or prevent the effect of CTGF on TIEG and/or Smad- 7 expression. Alternatively, the compound affects indirectly the interaction between CTGF and TIEG. In other words, the compound interacts with at least one fiirther compound, which in turn interacts with CTGF or TIEG in order to reduce and/or prevent the effect of CTGF on TIEG and/or Smad-7 expression.
In a second aspect of the invention there is provided a compound for use in the manufacture of a medicament for reduction and/or prevention of fibrosis characterised in that the compound reduces and/or prevents CTGF suppression of Smad 7 expression and or reduces and/or prevents induction of TIEG expression.
Preferably the compound is identified and/or made by the method of the first aspect of the invention.
Conveniently, the compound is at least one selected from polypeptides, antibody molecules and antisense nucleotides. Preferably the compound is an antibody molecule.
The term "antibody molecule" shall be taken to refer to any one of an antibody, an antibody fragment, or antibody derivative. It is intended to embrace wildtype antibodies, synthetic antibodies, recombii ant antibodies or antibody hybrids, such as, but not limited to, a single-chah modified antibody molecule produced by phage-display of immunoglobulin light and/or heavy chain variable and/or constant regions, or other inmiunohiteractive molecule capable of binding to an antigen hi an hnmunoassay format that is known to those skilled in the art. The term "antibody derivative" refers to any modified antibody molecule that is capable of bmding to an antigen in an immunoassay format that is known to those skilled in the art, such as a fragment of an antibody (e.g. Fab or Fv fragment), or a modified antibody molecule that is modified by the addition of one or more amino acids or other molecules to facilitate coupling the antibodies to another peptide or polypeptide, to a large carrier protein or to a solid support (e.g. the a ino acids tyrosine, lysine, glutamic acid, aspartic acid, cysteine and derivatives thereof, NH -acetyl groups or COOH-teπnrnal arnido groups, amongst others).
By "antisense oligonucleotides" we mean single-stranded nucleic acids, which can specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or RNA-DNA duplex is formed. These nucleic acids are often termed "antisense" because they are complementary to the sense or coding strand of the gene. Recently, formation of a triple helix has proven possible where the oligonucleotide is bound to a DNA duplex. It was found that oligonucleotides could recognise sequences in the major groove of the DNA double helix. A triple helix was formed thereby. This suggests that it is possible to synthesise sequence-specific molecules which specifically bind double-stranded DNA via recognition of major groove hydrogen binding sites.
By binding to the target nucleic acid, tlie above oligonucleotides can inhibit the function of the target nucleic acid. This could, for example, be a result of blocking the transcription, processing, poly (A) addition, replication, translation, or promoting inhibitory mechanisms of the cells, such as promoting RNA degradations. Antisense oligonucleotides are prepared in the laboratory and then introduced into cells, for example by microinjection or uptake from the cell culture medium into the cells, or they are expressed in cells after rransfection with plasmids or retroviruses or other vectors carrying an antisense gene.
In a third aspect of the invention there is provided a compound of the second aspect of the invention for use in the treahnent and/or prevention and/or diagnosis of a fibrotic disease.
Preferably the compound is used in the manufacture of a medicament for the treatment and/or prevention and/or diagnosis of a fibrotic disease.
Conveniently the fibrotic disease is one selected from diabetic nephropathy, non-diabetic kidney failure, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderrna, retinal fibrosis, radiation fibrosis, keloid scar formation and cancer-associated fibrosis
Preferably the disease is diabetic nephropathy.
hi a fourth aspect of the invention there is provided a method of treating and/or preventing fibrotic disease comprising amninistering a therapeutically or prophylactically effective dose, or plurality of doses, of a compound identified and/or made according to the method of the first aspect of the invention.
Conveniently the fib otic disease is one selected from diabetic nephropathy, non-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderma, retinal fibrosis, radiation fibrosis, keloid scar formation and cancer-associated fibrosis.
Preferably the disease is diabetic nephropathy.
Examples embodying certain preferred aspects of the invention will now be described with reference to the following figures in which:-
Figure 1 - CTGF inhibition of Smad 7 expression in FJMC
Serum-starved human mesangial cells (HMC) were exposed to rCTGF/V5 fusion protein for different periods of time, after which cell lysates were prepared and the Smad 7 and β-actin levels analysed by Western blotting. A representative blot of the three mdependent experiments (three rephcate cultures per condition per experiment) that were performed is shown.
Figure 2 - CTGF enhancement of phosphorylation and nuclear transiocation of Smad 2 and Smad 3 in HMC
Seram-starved HMC were exposed to TGF-β, rCTGF/V5 fusion protein, or both growth factors for 2 hours, after which nuclear extract (30 μg) was hnmunoprecipitated (IP) using phospho-serine affinity beads. Bomid proteins were then subjected to SDS-PAGE and Western blotting (WB) using Smad 2 and Smad 3 antibodies. A representative blot of the three independent experiments (three replicate cultures per condition per experiment) that were performed is shown. Figure 3 - Stimulation of TIEG levels by CTGF in HMC
Serum-starved HMC were exposed to rCTGF/V5 fusion protein for different periods of time, after which cell lysates were prepared and the TIEG and β-actin levels analysed by Western blotting. A representative blot of the three independent experiments (three replicate cultures per condition per experiment) that were performed is shown.
Figure 4 - TIEG mediates CTGF-dependent down-regulation of Smad 7 expression level.
Serum-starved HMC were exposed to tlie conditions indicated in the figure. After 24 h, cell lysates were prepared, and the TIEG, Smad 7, and β-actin levels analysed by Western blotting. A representative blot of the three independent experiments (three rephcate cultures per condition per experiment) that were performed is shown.
Figure 5 - CTGF enhances TGF-β-induced transcriptional activity of the SBE-luc reporter gene in HMC.
Cells were transfected with SBE-Luc. Six hours after transfection, the cells were incubated for a forfher 48 hours in serum-free media containing the indicated treatments. Luciferase activity was measured and normalised against β-galactosidase activity. The results (mean ± SEM) represent three independent experiments, with four replicates per condition per experhnent. Figure 6 - CTGF-dependent suppression of Smad7 is directly involved in the up-regulation of TGF-β-responsive genes.
Serum-starved cells were incubated for 48 hours under the conditions mdicated in the figure. RNA was extracted and used for semi-quantitative RT-PCR analysis of Smad 7, P15INK4, PAI-1, Col III and GAPDH.
(A) Experimental conditions and representative agarose gel analysis of PCR products. (B) Quantitation of PCR products by densitometry. Expression of each gene is shown as a ratio to GAPDH expression.
Three independent experiments were performed (four replicate cultures per condition per experiment).
EXAMPLES
Example 1 - Identification of CTGF- TIEG -Smad 7 interaction
Materials and Methods
Cell cultures, antibodies and reagents
Primary normal adult human mesangial cells (HMC) (CC-2259, lot 3F1510) (Biowhittaker, Wokingham, BerksMre, UK) were maintained in culture as described previously (Wahab et al. (1996) Biochem J. 316 pp. 985-992).
Antibodies against Smad 2, Smad 3 and Smad 7 were from Santa Cruz Biotechnology, Inc., (Autogen Bioclear, Calne, Wilts., UK). TGF-β inducible early gene (TLEG) antibodies were a gift from Dr. Steven Johnson (Mayo Foundation, Minnesota, USA). Recombinant CTGF was expressed in transformed HMC and purified from the medium using Talon metal affinity resin, as reported previously (Wahab et al (2001) Biochem J. 359 pp. 77-87). TGF-β was purchased from R & D Systems (Abingdon, Oxfordshire, U.K.). Phosphothioate antisense (TGG GCA GAC GAA CG) and control oligonucleotides (ACC GAC CGA CGT GT) directed to CTGF and antisense (TGT GTC TGG ACA GTT CAT) and control oligonucleotides (ACT ACT ACA CTA GAC TAC) directed to TIEG were designed and manufactured by Biognostik GmbH (Gδttingen, Geπnany). The SBE4-Luc reporter was a gift from Dr. B. Vogelstein (Zawel et al. (1998) Mol Ce/7 l pp.611-617). Table 1 - Primer sequences
Western blotting
Cells were lysed in reducing SDS-PAGE loading buffer and immediately scraped off the plate. Cell lysates were sonicated for 10 sec to shear DNA. Samples were boiled for 5 min and resolved on 4-12% gradient gels by SDS-PAGE. Proteins were transferred onto a polyvinyiidene difluoride membrane filter (Irmnobilin-P, MiUipore, Bedford, U.K.) ushig a BioRad transfer apparatus. Blots were incubated in blocking buffer containing Ix TBS, 0.1% Tween-20 with 5% (w/v) non-fat dry milk, for 1 hour.
Immunodetection was performed by incubating the blots in primary antibody at the appropriate dilution in antibody dilution buffer (lx TBS, 0.1% Tween-20 with 5% BSA), overnight at 4°C. Blots were then washed 3 times with washing buffer (lx TBS, 0.1% Tween-20) and incubated with secondary horseradish peroxidase (HRP)-conjugated antibodies for 1 hour at room temperature. Bound antibodies were visualised ushig the enhanced chemiluiniiiescence reagent Luniinol (Autogen Bioclear UK Ltd, Wiltslrire, UK). Pre- stained molecular weight standards (Amersham International PLC, Amersham, UK) were used to monitor protein migration.
Nuclear fraction preparation
Cells were scraped in ice-cold PBS, recovered by centrifugation at 500 x g for 10 min and resuspended in 500 μl of buffer A [10 mM Hepes, pH 7.4, 1.5 mM MgC12, 10 mM NaCl, lx protease inhibitors cocktail (1 mM
EDTA, 1 mM EGTA, 0.2 mM TLCK, 1 mM N-ethyhnaleimide, 0.1 mM TPCK, and 2 nM PMSF, Sigma), 1 mM NaF, 1 mM Na3V04].
After incubation on ice for 20 min, Nonidet P40 was added to a final concentration of 0.6% (v/v) and vigorously vortex-mixed for 10 seconds. The nuclei were pelleted at 4°C by centrifugation for 5 min at 12000 x g. The nuclear pellet was washed once with buffer A and coUected by centrifugation.
The pellet was then re-suspended in 500 μl of buffer B (10 rnM Hepes, pH 7.4, 1.5 mM MgC12, 450 mM NaCl, lx protease inhibitors cocktail, 1 mM NaF, ImM Na3V04, 20% (v/v) glycerol) and vortex-mixed for 15 min at 4°C. The lysate was centrifuged at 12000 x g for 5 min at 4°C and the supernatant containing the nuclear proteins transferred to a fresh vial. Protein concentration was measured by Bradford assay. Extracts were stored at -70°C until further use.
Use of antisense- oligonucleotides
TIEG and CTGF antisense oligonucleotide (2 μM) or a CG-matched randomised sequence oligonucleotide (negative control) was added directly to cultures 30 min prior any other treatments (Wahab et al (2002) J Am Soc Nephrol 13 pp .2437-2445).
Transient transfection and reporter gene assay
The SBE4-luc reporter gene construct was transfected into 25 x 106 transformed human mesangial cells (THMC), by electroporation, at a concentration of 15 μg together with 5 μg of pSV-β-galactosidase control Vector (Promega, Southampton, UK), using conditions described previously (Wahab et al (2001) Biochem J. 359 pp. 77-87).
Six hours after transfection, the cells were washed three times with PBS and then incubated for a further 48 hours h serum-free media containing different treatments. CeUs were then lysed in the Reporter Lysis Buffer (RLB) which permits both luciferase and β-galactosidase assays using Promega Kits. Luciferase activity was normalised to β-galactosidase activity to correct for any difference in transfection efficiency.
RNA extraction and RT-PCR analysis
Total RNA was extracted from 6 x 106 mesangial cells using the RNAzoLB method [AMS Biotechnology (UK) Ltd., Oxfordshire, UK]. RNA was dissolved in DEPC-dH20, quantitated and stored at -70°C. Equal amounts of total RNA (2 μg) from each sample were reverse transcribed into cDNAs ushig Superscript II RNase H+ reverse transcriptase (Gibco BRL, Paisley, Scotland, UK) and random primers.
Equal amounts (0.5 μl) of the reverse transcription reaction (20 μl) were subjected to PCR amplification hi a 100 μl volume containing 10 μl of 10 x PCR buffer, 16 μl dNTPs (1.25 mM each), 2 mM MgC12, 0.5 μM of each specific primer and 1.25 U Amplitaq DNA polymerase (Gibco BRL).
Amplification was started with 5 min of denaturation at 94°C, followed by 5 27 PCR cycles for all genes except the housekeeping gene glyceraldehyde- 3-phosphate dehydrogenase (GAPDH) where 24 PCR cycles were used. Each cycle consisted of 60 seconds at 94°C, 60 seconds at 55°C and 60 seconds at 72°C The final extension was for 10 min at 72°C. GAPDH was co-amplified to aUow semi-quantitative comparison of PCR products and to l o confirm equivalent use of total RNAs .
The amount of reverse transcription reaction used for the amplification (0.5 μl) was selected as being non-saturating for the PCR product of all genes under investigation after the stated number of amplification cycles. The 15 sequences of primers were designed from the published sequences of the human genes and are hsted in Table 1.
After amplification, 10 μl of each PCR reaction product was electrophoresed through a 1.2% (w/v) agarose gel containing ethidium 0 bromide (0.5 μg/ml). Gels were scanned using an Epson GT-8000 scanner and Adobe PhotoShop software. The results were normalised to the intensity of GAPDH bands.
Statistical analysis5 Results were compared using Student's unpaired t-test. A p value of 0.05 or less was regarded as denoting a significant difference. Results
Effect of CTGF on the expression of Smads in FIMC
In order to identify the molecular basis of the relationship between TGF-β and CTGF, the effect of CTGF on the Smad signalling pathway was investigated. Serum starved HMC were exposed to 20-40 ng/ml recombrnant CTGF/V5 fusion protein for up to 24 hours. Figure 1 shows that the expression of the inhibitory Smad 7 is reduced to a barely detectable level within 30-60 min after the addition of CTGF.
The effect of CTGF on the activation of receptor-regulated Smads (Smad 2 and Smad 3) was investigated by incubating serum-starved HMC in the presence or absence of CTGF, TGF-β, or in the presence of both CTGF and TGF-β for 2 hours.
Cells were then lysed and nuclear fraction proteins were prepared. Equal amounts of the nuclear protein fractions were immunoprecipitated using anti-phospho-serine affinity beads (Sigma). Immunoprecipitated proteins were Western blotted ushig anti-Smad 2 and anti-Smad 3 antibodies. Figure 2 shows that, TGF-β increases the phosphorylation and nuclear translocation of both Smads (lane 2). CTGF also increases the phosphorylation and nuclear translocation of Smad 2 and Smad 3 (lane 3). Both CTGF and TGF-β together increase the phosphorylation and nuclear franslocation of both Sniads hi a synergistic manner (lane 4). Thus Figure 2 indicates that CTGF-dependent reduction of Smad 7 expression leads to enhancement of the activation of Smad 2 and 3. CTGF regulation of TIEG
The effect of CTGF on tlie expression level of TIEG was then investigated. Figure 3 shows that CTGF exposure causes a rapid increase in the expression level of TIEG.
The ability of TIEG to directly mediate the CTGF-dependent down- regulation of Smad 7 levels was investigated by treating cells with TIEG antisense and control oligonucleotides. Figure 4 shows that the constitutive levels of both TIEG and Smad 7 proteins in HMC are low (lane 1).
Incubating the ceUs with CTGF for 24 hours markedly increases the TIEG level whilst reducing Smad 7 to an almost undetectable level (lane 2). This effect is completely abolished in the presence of TIEG antisense oligonucleotide (lane 5), but not by the control ohgonucleotide (lane 6).
incubating the cells with TGF-β alone for the same period of thne led to a moderate increase of both TIEG and Smad 7 (lane 3). However, incubating the cells with TGF-β in the presence of CTGF antisense oligonucleotide completely abolished the moderate induction of TIEG and led to the increased induction of Smad 7 (lane 7). This was not observed in the presence of the control antisense oligonucleotide (lane 8) and is consistent with TGF-β -induced CTGF being responsible for the observed moderate increase in TIEG expression level.
Similar results were also obtained by treating tlie cells with TIEG antisense and control antisense oligonucleotides (lanes 9 and 10). Incubating the cells with both TGF-β and CTGF (lane 4) markedly increases the expression level of TIEG whilst reducing the expression level of Smad 7. These results clearly show that TIEG mediates CTGF-dependent down-regulation of Smad 7 expression.
CTGF enhancement of the transcriptional activity of TGF-β
The effect of CTGF on the transcriptional activity of TGF-β was investigated ushig the TGF-b-regulated SBE-4 reporter construct which contains a palindromic Smad-binding element. The relative activity of the
SBE promoter in driving luciferase transcription in HMC incubated under different conditions for 48 hour was studied. Figure 5 summarises the results of three independent experiments.
Treatment with CTGF alone led to a 2.4-fold enhancement of basal activity of the promoter, whtie TGFβ led to a 7-fold enhancement.
TGF- β-enhanced activity was markedly reduced in the presence of either CTGF or TIEG antisense (3-2 fold) but not with the control oligonucleotides. The antisense, but not the control oligonucleotides, also markedly reduced the reporter activity when both TGF-β and CTGF were present together.
CTGF-dependent down-regulation of Smad 7 was also studied h relation to the upregulation of the TGF-β-responsive genes, pl5INK4, PAI-1, and collagen III. Semrn-starved cells were incubated for 48 hours in the presence of different combinations of CTGF, TGF-β, CTGF+TGF-β, CTGF+TIEG antisense and control oligonucleotides and either TGF- β+TGF antisense and control oligonucleotides or TIEG antisense and control oligonucleotides. RNA was extracted and used for semi-quantitative RT-PCR analysis. Figures 6A and B demonstrate that CTGF resulted h a 60% reduction of Smad 7 expression level. However, CTGF has no significant effect on either PAI-1 or collagen III gene transcription. In contrast, pl5 expression level appears to be enhanced (5-fold) under the same conditions.
The presence of TGF-β resulted in induction of transcription of all four genes as they contain one or more SBE in their promoters. The presence of CTGF together with TGF-β, resulted in reduction of Smad 7 (55%) and maximal induction of pi 5, PAI-1 and collagen III transcription. TGF-β- dependent increased transcription of these genes was inhibited between 30- 50% in the presence of either CTGF or TIEG antisense but not control oligonucleotides. These results are consistent with the induction of endogenous CTGF by TGF-β.
Under physiological conditions, TGF-β activity is limited by the negative feedback loop of the signalling pathway, provided by Smad 7. In contrast, under pathological conditions, where CTGF expression level is elevated, CTGF blocks this negative feedback loop by inhibition of Smad 7 expression via TIEG, allowing continued activation of the TGF-θ signalling pathway.
Example 2 - Screening method for identifying compounds inhibitin CTGF induced fibrosis
Screening for compounds possessing fibrosis inhibitory properties is conducted by testing the ability of each compound to block, for example, the induction of TIEG hi HMC treated with CTGF. The screening method is conducted using human mesangial cells (HMC) pre-incubated for 30 lninutes with or without the potential inhibitor. These cells are then stimulated with CTGF-V5 fusion protein (40 ng/ml) in the presence or absence of the potential inhibitor for 2 hours. After washing the cell layer with cold PBS, the cells are lysed in RIP A buffer and the lysate assayed for TIEG by ELISA.
For the ELISA assay (Voller A et al, (1976) in Manual of Clinical Immunology (Rose, N and Fishman H, eds.) pp 506-512, American Society of Microbiology, Washington, DC), NUNC microtifre plates are coated overnight at 4°C with either lysate or with standard dilutions of r-TIEG to provide a standard curve.
After removing the coating solutions and washing the wells briefly with PBS, non-specific proteins are blocked by incubating the weUs for 1 hour withl% (w/v) bovine serum albumin in PBS at 37°C. WeUs are then incubated with anti-TIEG antibody at optimal dilution for 60 minutes, followed by peroxidase conjugated secondary antibody for 60 minutes at 37°C. After washing the wells three times with PBS, bound antibody is detected with the substrate 2,2'-azinobis-3-ethylbenzthazoline 6-sulphonic acid and absorbance read at 405 nm.
Recombinant TIEG protein is created from full length TIEG cDNA by cloning into the PcDNA 3.1/V5-His Topo vector (InVitrogen). This vector can be transfected hito a mammalian cell line to express TIEG-fusion protein.
The TIEG fusion protein is purified from cell lysates using probond nickel- chelating resin. Anti-TIEG antibody is available from Dr. Steven Johnson (Mayo Foundation, Minnesota, USA) or can be raised in rabbits against the TIEG fusion protein using conventional methods.
Example 3 - Pharmaceutical formulations and administration.
The compounds of the invention wUl normally be adrninistered orally or by any parenteral route, in the form of a pharmaceutical formulation comprising the active ingredient, optionally in the form of a non-toxic organic, or inorganic, acid, or base, addition salt, in a pharmaceutically acceptable dosage foπn. Depending upon the disorder and patient to be treated, as well as the route of administration, the compositions may be administered at varying doses.
hi human therapy, the compounds of the invention can be adnhnistered alone but will generally be administered in admixture with a suitable pharmaceutical excipient diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
For example, the compounds of the invention can be administered orally, buccaUy or sublingually in the form of tablets, capsules, ovules, elixhs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed- or controlled-release applications. The compounds of the invention may also be aώninistered via intracaveπiosal injection.
Such tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably com, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation bhiders such as polyvinylpyrxolidone, hydroxypropylmethylcellulose (HPMC), hydroxy-propylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as 'magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
Solid compositions of a sinrUar type may also be employed as fillers in gelatin capsules. Preferred excipients hi this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and or elixhs, the compounds of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
The compounds of the invention can also be adniinistered parenteraUy, for example, intravenously, intra-arterially, intraperitoneally, intrathecaUy, intraventricularly, intrastemally, infracranially, intra-muscularly or subcutaneously, or they may be administered by infusion techniques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled hi the art.
Formulations suitable for parenteral amnmisfration hiclude aqueous and non- aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the ήitended recipient; and aqueous and non-aqueous sterile suspensions
20 which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, hnmediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
For oral and parenteral administration to human patients, the daily dosage level of the compounds of the mvention will usually be from 1 mg/kg to 30 mg/kg. Thus, for example, the tablets or capsules of the compound of the invention may contain a dose of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
The compounds of the invention can also be adnhnistered hitranasally or by hihalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised contahier, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoroniethane, trichlorofluoromethane, dichlorotetrafluoro- ethane, a hydrofluoraalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A3 or 1,1,1,2,3,3,3-heptafluoropiOpane (HFA 227EA3), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g. ushig a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the mvention and a suitable powder base such as lactose or starch.
Aerosol or dry powder formulations are preferably arranged so that each metered dose or "puff delivers an appropriate dose of a compound of the invention for delivery to the patient. It will be appreciated that the overall dahy dose with an aerosol wiU vary from patient to patient, and may be administered in a single dose or, more usually, in divided doses throughout the day.
Alternatively, the compounds of the invention can be administered in the form of a suppository or pessary, or they may be applied topicaUy in the form of a lotion, solution, cream, ointment or dusting powder. The compounds of the invention may also be transdermally adrninistered, for example, by the use of a skin patch. They may also be aώninistered by the ocular route, particularly for treating diseases of the eye.
For ophthalmic use, the compounds of the invention can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions hi isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.
For application topically to the skin, the compounds of the mvention can be formulated as a suitable ointment containing the active compound n o suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyox}φropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved hi, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol and water.
Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usuaUy sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouth-washes comprising the active ingredient in a suitable liquid carrier.
Generally, in humans, oral or topical administration of the compounds of the invention is the preferred route, being the most convenient. In circumstances where the recipient suffers from a swallowing disorder or from hnpaiπnent of drug absorption after oral administration, the drug may be administered parenteraUy, e.g. sublingually or buccaUy.
For veterinary use, a compound of the invention is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will detemih e the dosing regimen and route of administration which will be most appropriate for a particular animal.

Claims

1. A method for identifying and/or making compounds for use in reduc ig and or preventing fibrosis, comprising the steps:
(a) providing a cell type capable of expressing TIEG and/or Smad-7;
(b) providing a test compound; (c) providing an amount of CTGF or a functional equivalent thereof;
(d) exposing the cell type to the test compound;
(e) subsequently or simultaneously exposing the cell type to the CTGF or a functional equivalent thereof;
(f) detecting and/or measuring the production of Smad-7 and/or TIEG; (g) comparing the amount of Smad-7 and/or TIEG expressed in the presence of the test compound with the amount of Smad-7 and/or TIEG expressed detected and/or measured in the absence of the test compound; and (h) detennhring if a compound reduces and/or prevents fibrosis on the basis that it causes no change or an increase in Smad-7 expression and or no change or a decrease in TIEG expression.
2. The method of Claim 1 further comprising the step of:
(i) isolation of a test compound resulting in no change or an increase hi Smad-7 expression and/or no change or a decrease in TIEG expression.
3. The method of Claim 2 -further comprising the step of
(j) formulating the isolated compound into a composition further comprising a pharmaceutically acceptable carrier, excipient and or diluent.
4. The method of any previous Claim wherein the compound interacts directly with the interaction between CTGF and TIEG.
5. The method of any of claims 1 to 3 wherein the compound interacts indirectly with the interaction between CTGF and TIEG.
6. A compound which is capable of reducing and/or preventing the activity of CTGF in the induction of TIEG expression and/or suppression of Smad-7 expression.
7. A compound identified and/or made by the method of any of claims 1 to 5 for use in reducing and/or preventing the activity of CTGF in the induction of TIEG expression and/or suppression of Smad-7 expression.
n i J l
8. A compound as claimed in either of Clahns 6 and 7 which is at least one selected from polypeptides, antibody molecules and antisense nucleotides.
9. A compound as clahned in Claim 8 wherein the compound is an antibody molecule.
10. A compound as clahned in Claim 8 wherein the compound is an antisense nucleotide.
11. Use of a compound identified and/or made by the method of any of claims 1 to 5 in the treatment and/or prevention and/or diagnosis of a fibrotic disease.
12. Use of a compound identified and/or made by the method of any of claims 1 to 5 in the manufacture of a medicament for the treatment and/or prevention and/or diagnosis of a fibrotic disease.
13. A use as claimed in any one of Claims 11 or 12 wherein the fibrotic disease is one selected from diabetic nephropathy, non-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderma, retinal fibrosis, radiation fibrosis, keloid scar formation and cancer-associated fibrosis.
14. A use as claimed hi Claim 13 wherein the disease is diabetic nephropathy.
15. A method of treating and or preventing a fibrotic disease comprising administering a therapeutically or prophylactically effective dose, or plurality of doses, of a compomid identified and/or made by the method of any of Claims 1 to 5.
16. A method of treating and/or preventing a fibrotic disease comprising administering a therapeutically or prophylactically effective dose, or plurality of doses, of a compound as claimed in any of Claims 6 to 10.
17. A method as claimed in either Clahns 15 or 16 wherein the fibrotic disease is one selected from diabetic nephropathy, non-diabetic kidney fibrosis, lung fibrosis, liver fibrosis (cirrhosis), skeletal muscle fibrosis, cardiac muscle fibrosis, atherosclerosis, systemic sclerosis, scleroderma, retinal fibrosis, radiation fibrosis, keloid scar formation and cancer-associated fibrosis.
18. A use as claimed in Claim 17 wherein the disease is diabetic nephropathy.
53
EP04798502A 2003-11-18 2004-11-12 Biological materials and uses thereof Withdrawn EP1690098A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326778.8A GB0326778D0 (en) 2003-11-18 2003-11-18 Biological materials and uses thereof
PCT/GB2004/004781 WO2005050202A2 (en) 2003-11-18 2004-11-12 Biological materials and uses thereof

Publications (1)

Publication Number Publication Date
EP1690098A2 true EP1690098A2 (en) 2006-08-16

Family

ID=29763970

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04798502A Withdrawn EP1690098A2 (en) 2003-11-18 2004-11-12 Biological materials and uses thereof

Country Status (7)

Country Link
EP (1) EP1690098A2 (en)
JP (1) JP2007515161A (en)
CN (1) CN1906490A (en)
AU (1) AU2004292012A1 (en)
CA (1) CA2546397A1 (en)
GB (1) GB0326778D0 (en)
WO (1) WO2005050202A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CN103429270B (en) * 2008-08-25 2016-11-23 埃克斯雷德制药有限公司 Stop antisense nucleotide of Connective Tissue Growth Factor and application thereof
SI2670411T1 (en) 2011-02-02 2019-06-28 Excaliard Pharmaceuticals, Inc. Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
CN104487574B (en) 2012-04-18 2017-07-07 诺格尔制药有限公司 Treatment diabetes and/or the method for promoting survival after pancreatic islets transplantation
CN117677692A (en) * 2021-05-21 2024-03-08 江苏九济华生医药科技研究院有限公司 Cell strain for TGF beta detection and high-precision TGF beta detection method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773278B2 (en) * 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
WO2001015729A1 (en) * 1999-08-27 2001-03-08 Fibrogen, Inc. Connective tissue growth factor receptor, its agonists and antagonists, and their therapeutic and diagnostic uses
GB0326780D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005050202A2 *

Also Published As

Publication number Publication date
CN1906490A (en) 2007-01-31
WO2005050202A2 (en) 2005-06-02
CA2546397A1 (en) 2005-06-02
AU2004292012A1 (en) 2005-06-02
GB0326778D0 (en) 2003-12-24
JP2007515161A (en) 2007-06-14
WO2005050202A3 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
US10047396B2 (en) Biomarkers for diagnosis of transient ischemic attacks
Bantel et al. Critical role of nuclear factor‐κB and stress‐activated protein kinases in steroid unresponsiveness
US20050136429A1 (en) SIRT1 modulation of adipogenesis and adipose function
JP2010042019A (en) Marker gene
US20060223104A1 (en) Methods and compositions for modulating necdin function
JP2009501521A (en) Methods for diagnosing and treating inflammatory responses
Yarushkin et al. The constitutive androstane receptor activator 4‐[(4R, 6R)‐4, 6‐diphenyl‐1, 3‐dioxan‐2‐yl]‐N, N‐dimethylaniline inhibits the gluconeogenic genes PEPCK and G6Pase through the suppression of HNF4 α and FOXO1 transcriptional activity
Cui et al. Regulation of tissue factor gene expression in epithelial cells. Induction by serum and phorbol 12-myristate 13-acetate.
AU2004292013A1 (en) Methods for screening using CTGF and TRKA receptor for the identification of compounds for use in treatment of fibrosis
US20080145883A1 (en) Biomarker in inflammatory diseases
WO2005050202A2 (en) Biological materials and uses thereof
US20160299155A1 (en) Methods for diagnosing osteoarthritis
Elsby et al. Hypoxia and glucocorticoid signaling converge to regulate macrophage migration inhibitory factor gene expression
Safronova et al. Regulation of chemokine gene expression by hypoxia via cooperative activation of NF-κB and histone deacetylase
CA2487730A1 (en) Sgk and nedd used as diagnostic and therapeutic targets
US8192945B2 (en) Method for screening compounds to determine those which enhance islet cell activity and/or survival and uses therefor
EP1880219B1 (en) Gpr18 as a biomaker for th1 mediated immune response
EP1658504B1 (en) Inhibition of s6 kinase activity for the treatment of insulin resistance
US20040259136A1 (en) Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases
US20080064027A1 (en) TEL/Etv6-mediated inhibition of cell proliferation
EP1556505A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
Dabral Role of Notch signaling in pulmonary hypertension
JP2005503787A (en) Methods for identifying substances that positively affect inflammatory symptoms
Grigorov Association of the Glucocorticoid Receptor with STAT3, C/EBPß and the Hormone Responsive Element within the Rat Haptoglobin Gene Promoter during the Acute Phase
Beck Glucocorticoid receptor-based transrepressive mechanisms at promoters of inflammatory genes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060619

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMPERIAL INNOVATIONS LIMITED

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1091264

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080603

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1091264

Country of ref document: HK